MARKET WIREYahoo Finance • 22h ago
Is AstraZeneca (AZN) Stock Cheap?Yahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
Why AZN Stock Traded Steady Today — RQD Quant Desk Flash
$186.58 -0.04% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $186.21
AstraZeneca PLC (AZN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $289.44B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, AstraZeneca PLC (NYSE: AZN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $186.58 (-0.04% 1D, market cap $289.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AZN ranks #99 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AZN compare to NVS and MRK in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C+ (67/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (67/100 RQD, P/E 32.8x, ROIC 9.9%, cap $306.81B) and MRK (Merck & Company Inc.) posts a B+ grade (80/100 RQD, P/E 19.8x, ROIC 20.7%, cap $368.89B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AZN?
▼
For AstraZeneca PLC (AZN), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $186.21 (-0.20%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 15.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AZN)Realized 20D OHLCV Swing Band: ±4.9%
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY AZN SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (24% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)
20D Institutional Volume Accumulation (±4.9% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)
Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$162.03+4% Next Q
59
Q2 (-2Q)Grade C+$168.45+0.6% Next Q
62
Q3 (-1Q)Grade C+$169.51+10.1% Next Q
64
CurrentGrade C+$186.58+1.6% Hist 90D α
67
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the AZN Bull Thesis Could Fail
Even with a 67/100 (C+) score, AZN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($165.14) or 200D SMA ($180.05) invalidates the momentum regime and cuts Target Base ($194.14) toward Bear Floor ($151.43).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AZN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AZN Stock Traded Steady Today — RQD Quant Desk Flash
AstraZeneca PLC (AZN) slipped -0.04% to $186.58, trading at 56% of its 52-week range ($153.41 – $212.71). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 56% of its 52-week range ($153.41 – $212.71) with RSI-14 at 66.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.9% around $186.58 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 52% gross margin and $6.4B annual free cash flow.
Live AZN Headlines & Catalysts
CATALYSTReuters • 1d ago
AstraZeneca CEO strikes bullish tone on pipeline as stock ralliesReuters report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Why Is AstraZeneca Stock Trading Higher Today? - AstraZeneca (NYSE:AZN)Benzinga report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current EarningsYahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full AnalysisTradingKey report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
CATALYSTStocktwits • 1d ago
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’Stocktwits report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?Yahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
AstraZeneca (LSE:AZN) Stock Trades At A Discount To Cash Flow ValueYahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
OncoC4 Appoints Dr. Dan Janiak as Chief Business OfficerOncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and immunological diseases, today announced the appointment of Dr. Dan Janiak as Chief Business Officer.
RISK WATCHBenzinga • 1d ago
Top 3 Health Care Stocks That May Fall Off A Cliff This QuarterRegeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (AZN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.70%⚡ TESTING RESISTANCE
2026-11-03O $174.4H $186.7L $174.4C $186.6VOL 5.47M
RES: $189.0SUP: $154.2SMA50: $165.1SMA200: $180.1
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth
vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on AZN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AZN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AZN)
Health Care Rank #99 of 1015
⚔️ NVS vs AZN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AZN vs. NVS, MRK, ABT, NVO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, AstraZeneca PLC (AZN) ranks #99 by composite RQD confidence (67/100, grade C+) and #8 by equity capitalization ($289.44B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while MRK leads on capital efficiency and profitability with 20.7% ROIC and 74.8% gross margin. MRK currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with AZN at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AZN
ACTIVE
AstraZeneca PLC | C+ | 67/100 | 32.8x | — | 9.9% | -0.04% | $289.44B | Benchmark Subject |
| NVS Novartis AG | C+ | 67/100 | 32.8x | — | 9.9% | +0.45% | $306.81B | /nvs-vs-azn → |
| MRK Merck & Company Inc. | B+ | 80/100 | 19.8x | 74.8% | 20.7% | -0.78% | $368.89B | /mrk-vs-azn → |
| ABT Abbott Laboratories | B+ | 77/100 | 27.7x | 56.4% | 11.9% | +3.73% | $183.77B | /abt-vs-azn → |
| NVO Novo Nordisk A/S | D+ | 58/100 | 32.8x | — | 9.9% | +1.13% | $177.12B | /nvo-vs-azn → |
2. AZN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTAstraZeneca PLC (AZN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $289.44B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
3. AZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, AstraZeneca PLC (NYSE: AZN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $186.58 (-0.04% 1D, market cap $289.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AZN ranks #99 in composite RQD confidence.
How does AZN compare to NVS and MRK in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C+ (67/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (67/100 RQD, P/E 32.8x, ROIC 9.9%, cap $306.81B) and MRK (Merck & Company Inc.) posts a B+ grade (80/100 RQD, P/E 19.8x, ROIC 20.7%, cap $368.89B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AZN?
For AstraZeneca PLC (AZN), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AZN trading relative to its 50-day, 200-day, and 52-week technical levels?
AZN last traded at $186.58 (-0.04% on volume of 2,699,448 shares), positioning the stock +12.98% above its 50-day simple moving average ($165.14) and +3.63% above its 200-day simple moving average ($180.05). Across its 52-week range of $153.41 to $212.71, AZN sits at the 55.9% percentile with a 14-day RSI of 66.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.9% ($177.44 to $195.72).
ROARABLE RATING BRIEF • RQD 67/100 (C+)
✓ SEC XBRL & RQD VERIFIED
AZN — AstraZeneca PLC: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
AstraZeneca PLC (AZN) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $186.58 (-0.04% 1D, market capitalization $289.44B).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
- Whale 13F & Options Flow (15/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 0.91x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.
2. Business Model, Unit Margins & SEC Financial Trajectory
AstraZeneca PLC is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, operating margin is 13.9% and net margin is 10.9%. — for product lines, customer segments, or specific revenue-generation mechanics.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C+ • RQD 67/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $153.41 – $212.71 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 0.91x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only relevant ripple evident in the news wire is the Ionis-partnered heart-drug trial miss referenced in the Stocktwits item, which investors may wish to track for pipeline read-through.
- Key Question #1: Can AZN sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $212.71 52-week high?
- Key Question #3: How sensitive is AZN's 27.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?
AZN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for AstraZeneca PLC (AZN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 22h ago
Is AstraZeneca (AZN) Stock Cheap? Yahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Reuters • 1d ago
AstraZeneca CEO strikes bullish tone on pipeline as stock rallies Reuters report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Why Is AstraZeneca Stock Trading Higher Today? - AstraZeneca (NYSE:AZN) Benzinga report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings Yahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis TradingKey report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 1d ago
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ Stocktwits report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity? Yahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
AstraZeneca (LSE:AZN) Stock Trades At A Discount To Cash Flow Value Yahoo Finance report covering AstraZeneca PLC (AZN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AZN Bull vs. Bear Conversation Board — What's Your Call at $186.58?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AZN 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $218.38 (+17.0%)
📌 Pinned Debate Forensic balance sheet scores 16/20 with Altman Z 3.74 and Piotroski F 8/9, and the CEO's pipeline commentary coincided with a stock ra
The street is overcomplicating AstraZeneca PLC (AZN). Forensic balance sheet scores 16/20 with Altman Z 3.74 and Piotroski F 8/9, and the CEO's pipeline commentary coincided with a stock rally.. With an RQD score of 67/100 (C+) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $201.58.
ArenaChamp_24 🐂 BULL
@AlphaFlow_Cap Agree on the RQD 67/100 quality, though with 0.91 beta I'm scaling in with half-size at $186.65 and keeping dry powder in case we test $173.58.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $156.79 (-16.0%)
Spot @ $186.65 Trailing P/E of 32.8 against a 2.21% FCF yield and a 9/20 macro-regime-fit score leave limited valuation cushion.
I respect the product at AstraZeneca PLC, but the stock at $186.65 is a different story. Trailing P/E of 32.8 against a 2.21% FCF yield and a 9/20 macro-regime-fit score leave limited valuation cushion.. FCF yield is 2.21% and RQD sits at 67/100 (C+) — why pay up here when you can wait for next quarter's numbers?